Arctic Bioscience - Data on systemic inflammation published in Frontiers in Medicine
2026-08-05 08:06:21
Arctic Bioscience announces that new data on resolution of systemic inflammation
in psoriasis and herring roe oil (HRO) has been published in the peer-reviewed
journal Frontiers in Medicine. This was a post-hoc examination of blood-based
markers of inflammation in patients who participated in the Haukeland psoriasis
clinical trial (2019).
The analysis found that patients with mild-to-moderate psoriasis who received
herring roe oil for 26 weeks showed significant reduction in several biomarkers
of inflammation compared with placebo. These biomarkers can provide information
about inflammation throughout the body. The findings also suggest that certain
biomarkers may help identify which patients are most likely to benefit from
treatment.
"Psoriasis is often thought of as a skin disease, but it can affect the whole
body. These findings help us better understand what may be happening beneath the
skin surface, and the research is part of our commitment to improving patients'
health and quality of life", says Medical Director, Runhild Gammelsæter.
"Systemic inflammation can play an important role in psoriasis, even in patients
with milder disease. The reductions observed in these inflammatory biomarkers
suggest that herring roe oil may help support the body's natural processes for
resolving inflammation. We look forward to publishing further data on these
biomarkers from the larger HeROPA Phase 2b clinical trial on HRO350", concludes
Gammelsæter.
HRO350 is an investigational medicinal product currently being developed as a
potential new oral treatment for mild-to-moderate psoriasis, a large patient
population that continues to need effective therapies with favorable safety and
tolerability profiles. The data on systemic inflammation will be important in
the ongoing planning of a potential Phase 3 clinical trial.
The research was carried out in collaboration with Dr. Kåre Steinar Tveit at
Haukeland University Hospital in Norway.
Reference:
Ringheim-Bakka TA, Gammelsaeter R and Tveit KS (2026) Resolution of systemic
inflammation in psoriasis following herring roe oil treatment: a post hoc
analysis on inflammatory biomarkers in non-severe psoriatic patients. Front.
Med. 13:1861341.
doi: 10.3389/fmed.2026.1861341.
Link to publication:
https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2026.1861341
/
full
The publication will be made available on the IR tab on the company's webpage.
For further information, please contact:
Christer L. Valderhaug
CEO
Mobile: +47 920 84 601
Email: christer@arctic-bioscience.com
About Arctic Bioscience
Arctic Bioscience is a biotech company developing and commercializing
pharmaceutical and nutraceutical products based on unique bioactive marine
compounds.
The company is developing HRO350 - a novel oral drug candidate. HRO350 is being
developed for treatment of patients with mild-to-moderate psoriasis. This is a
large patient group in need of new effective medicines with beneficial safety
profile.
Nutraceuticals from Arctic Bioscience are sold globally as bulk ingredients as
well as finished goods under the ROMEGA® brand.
Arctic Bioscience is led by a highly skilled team of talents with diverse and
highly relevant background.
led by a highly skilled team of talents with diverse and\
highly relevant background.\